ES2965957T3 - Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer - Google Patents
Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2965957T3 ES2965957T3 ES17729078T ES17729078T ES2965957T3 ES 2965957 T3 ES2965957 T3 ES 2965957T3 ES 17729078 T ES17729078 T ES 17729078T ES 17729078 T ES17729078 T ES 17729078T ES 2965957 T3 ES2965957 T3 ES 2965957T3
- Authority
- ES
- Spain
- Prior art keywords
- polypeptide
- immune checkpoint
- checkpoint inhibitor
- cancer
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2965957T3 true ES2965957T3 (es) | 2024-04-17 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17729078T Active ES2965957T3 (es) | 2016-06-02 | 2017-06-02 | Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (enExample) |
| EP (2) | EP3463436B1 (enExample) |
| JP (2) | JP7321709B2 (enExample) |
| AU (1) | AU2017275782B2 (enExample) |
| CA (1) | CA3026172A1 (enExample) |
| DK (1) | DK3463436T3 (enExample) |
| ES (1) | ES2965957T3 (enExample) |
| FI (1) | FI3463436T3 (enExample) |
| HR (1) | HRP20231650T1 (enExample) |
| HU (1) | HUE065176T2 (enExample) |
| LT (1) | LT3463436T (enExample) |
| PL (1) | PL3463436T3 (enExample) |
| PT (1) | PT3463436T (enExample) |
| RS (1) | RS65007B1 (enExample) |
| SI (1) | SI3463436T1 (enExample) |
| WO (1) | WO2017207814A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2536830T3 (pl) | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| US11419927B2 (en) | 2016-06-02 | 2022-08-23 | Ultimovacs As | Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| GB201803178D0 (en) | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| CN112368016A (zh) * | 2018-06-29 | 2021-02-12 | 大鹏药品工业株式会社 | 抗肿瘤剂及其评价方法 |
| CA3222077A1 (en) | 2021-06-09 | 2022-12-15 | Dana Michel | A conjugate |
| WO2024083867A1 (en) * | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383424C (en) | 1999-08-23 | 2011-02-15 | Gordon Freeman | Novel b7-4 molecules and uses therefor |
| EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
| IL164287A0 (en) | 2002-04-12 | 2005-12-18 | Medarex Inc | Methods of treatment using ctla-4 antibodies |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| PL2536830T3 (pl) * | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| ES2616258T3 (es) | 2010-03-15 | 2017-06-12 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| HK1212237A1 (en) | 2012-08-31 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| CN105073135A (zh) | 2013-02-22 | 2015-11-18 | 库瑞瓦格有限责任公司 | 疫苗接种和抑制pd-1途径的组合 |
| MX369709B (es) | 2013-03-15 | 2019-11-19 | Univ Pennsylvania | Vacunación mejorada contra tirosinasa. |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| WO2015089114A1 (en) | 2013-12-09 | 2015-06-18 | Bullet Biotechnology, Inc. | Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US9903102B2 (en) | 2013-12-27 | 2018-02-27 | Xiamen Solex High-Tech Industries Co., Ltd. | Concealed embedded component for a waterway system |
| EA035259B1 (ru) | 2014-02-14 | 2020-05-21 | Иммьюн Дизайн Корп. | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| EP3142690B1 (en) | 2014-05-13 | 2022-02-23 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| JP2017515841A (ja) | 2014-05-13 | 2017-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| EP3164157A4 (en) | 2014-07-01 | 2018-02-28 | Vicus Therapeutics, LLC | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| WO2016007504A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| JP2017522322A (ja) | 2014-07-18 | 2017-08-10 | アドバクシス， インコーポレイテッド | 抗腫瘍応答を引き出すためのリステリアベースの免疫原性組成物 |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| CA2966132A1 (en) | 2014-10-23 | 2016-04-28 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| JP7305300B2 (ja) | 2014-11-05 | 2023-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 併用免疫療法 |
| EP3733201A1 (en) | 2016-01-19 | 2020-11-04 | Pfizer Inc | Cancer vaccines |
| US11419927B2 (en) | 2016-06-02 | 2022-08-23 | Ultimovacs As | Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3463436T (pt) | 2023-12-28 |
| DK3463436T3 (da) | 2023-12-18 |
| PL3463436T3 (pl) | 2024-03-04 |
| EP4253419A2 (en) | 2023-10-04 |
| SI3463436T1 (sl) | 2024-02-29 |
| US20230049012A1 (en) | 2023-02-16 |
| RS65007B1 (sr) | 2024-01-31 |
| US20190247482A1 (en) | 2019-08-15 |
| EP4253419A3 (en) | 2024-05-22 |
| HUE065176T2 (hu) | 2024-05-28 |
| JP7321709B2 (ja) | 2023-08-07 |
| AU2017275782A1 (en) | 2019-01-24 |
| US12168045B2 (en) | 2024-12-17 |
| LT3463436T (lt) | 2024-01-25 |
| CA3026172A1 (en) | 2017-12-07 |
| JP2022171684A (ja) | 2022-11-11 |
| EP3463436B1 (en) | 2023-09-20 |
| EP3463436A1 (en) | 2019-04-10 |
| FI3463436T3 (fi) | 2023-12-04 |
| WO2017207814A1 (en) | 2017-12-07 |
| HRP20231650T1 (hr) | 2024-05-10 |
| JP2019517508A (ja) | 2019-06-24 |
| US11419927B2 (en) | 2022-08-23 |
| AU2017275782B2 (en) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2965957T3 (es) | Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer | |
| Melssen et al. | Vaccines targeting helper T cells for cancer immunotherapy | |
| Farkona et al. | Cancer immunotherapy: the beginning of the end of cancer? | |
| Koido et al. | Immunotherapy for colorectal cancer | |
| US11529403B2 (en) | Telomerase polypeptide vaccine for treating cancer | |
| JP5787752B2 (ja) | 抗腫瘍免疫療法 | |
| ES2992110T3 (es) | Nueva inmunoterapia contra diversos tumores como el cáncer gastrointestinal y gástrico | |
| CA2934073A1 (en) | Combination therapy with neoantigen vaccine | |
| BR112015022367B1 (pt) | Vacina, molécula de ácido nucleico, e, molécula de aminoácido | |
| JP2021038225A (ja) | ネコ用がんワクチン | |
| WO2021074655A1 (en) | Cancer vaccine | |
| Franks et al. | New anticancer immunotherapies | |
| AU2013210783A1 (en) | Autologous cancer cell vaccine | |
| ES2357548T3 (es) | Péptido poli-epitope derivado de timidilato sintasa que tiene actividad inmunológica y antitumoral. | |
| Bot et al. | Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions | |
| Tsang et al. | Insights on peptide vaccines in cancer immunotherapy | |
| WO2024083866A1 (en) | Cancer treatment | |
| Naz et al. | Prophylactic vaccines for prevention of prostate cancer | |
| CA2861565C (en) | Autologous cancer cell vaccine | |
| Wang et al. | Modulatory effects of tumor-derived heat shock protein in DNA vaccination against nasopharyngeal carcinoma | |
| TR201811683A2 (tr) | OTOLOG NK (Natural Killer) HÜCRELERİNİN OTOLOG KANSER HÜCRELERİYLE EŞ ZAMANLI KÜLTÜRE EDİLİP İMMUNİZE EDİLMESİ İLE KANSER AŞI TEDAVİSİ | |
| Hu | Multiple Vaccinations |